Group Sequential Methods with Applications to Clinical Trials

Par : Christopher Jennison, Bruce W. Turnbull
  • Nombre de pages390
  • FormatGrand Format
  • PrésentationRelié
  • Poids0.765 kg
  • Dimensions16,0 cm × 24,2 cm × 2,8 cm
  • ISBN0-8493-0316-8
  • EAN9780849303166
  • Date de parution01/01/2000
  • ÉditeurCRC Press

Résumé

In clinical trials of new medical treatments, it is standard practice to monitor accumulating data on patient response at regular intervals. Specialized statistical methods are needed to balance the ethical and financial advantages of stopping a study early against the risk of an incorrect conclusion. These are referred to as "group sequential" methods. Research in group sequential analysis has progressed rapidly over the past 20 years.
Theory, computation and simulation now provide a firm foundation for methods meeting the key practical needs. Group Sequential Methods with Applications to Clinical Trials surveys and extends current methods for planning and conducting interim analyses. It describes group sequential stopping rules which can reduce average study length while controlling error probabilities. Procedures are presented in a manner which allows their easy implementation to the wide variety of data types arising from clinical trials.
Group Sequential Methods with Applications to Clinical Trials is an invaluable aid for medical statisticians in the pharmaceutical industry, medical research institutes and hospitals, as well as academic statisticians in biostatistics and epidemiology.
Christopher Jennison is Professor of Statistics in the Department of Mathematical Sciences, University of Bath, UK. He has worked on the analysis of clinical trials at the Dana-Farber Cancer Institute, Boston and collaborated with medical researchers in areas such as cancer research, cardiology, gynecology and complementary medicine. Bruce Turnbull is Professor of Statistics in the School of Operations Research & Industrial Engineering and in the Department of Statistical Science, Cornell University, USA.
He has a long experience of designing, monitoring and analyzing clinical trials and has served on the Data Safety Monitoring Boards for international, multi-center trials for the treatment or prevention of cancer, heart disease and AIDS. He has also served as a consultant to pharmaceutical companies and health-related government review panels.